Under the three agreements, Selexis will develop: a cell line for a naked antibody; a new cell line for a bispecific antibody; and a new cell line for the expression of a complex recombinant vaccine protein.
“Our SUREtechnology Platform provides an option that biopharmaceutical companies may consider for developing both biologics and vaccine treatments,” said Marco Bocci, vice president, licensing and business development, Selexis. “It’s rewarding to work with Sanofi across multiple applications including vaccines.”
According to Selexis, its proprietary SUREtechnology Platform supports the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the biologics and vaccine development continuum, spanning discovery to commercialization.
“Selexis’ technologies are innovative and nimble. We adapt to the required needs of global biopharmaceutical companies with robust pipelines targeting multiple therapeutic areas and various modes of drug and vaccine development,” said Igor Fisch, chairman and chief executive officer, Selexis. “We offer a one-stop solution to our partners, and this model is validated by the continued expansion of our collaborations, many of which are long-term relationships as these companies advance their candidates through the clinical development process to biologics and vaccine manufacturing.”